Legal & General Group
NPCE icon

Legal & General Group’s Neuropace NPCE Stock Holding History

Legal & General Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Buy
2,586
+396
+18% +$6.37K ﹤0.01% 2832
2026
Q1 		$28.8K Sell
2,190
-412
-16% -$6.18K ﹤0.01% 2845
2025
Q4 		$40.2K Sell
2,602
-77
-3% -$1.03K ﹤0.01% 2787
2025
Q3 		$27.6K Hold
2,679
– – ﹤0.01% 2917
2025
Q2 		$29.8K Buy
2,679
+1,239
+86% +$15.5K ﹤0.01% 2851
2025
Q1 		$17.7K Sell
1,440
-68
-5% -$851 ﹤0.01% 2983
2024
Q4 		$16.9K Hold
1,508
– – ﹤0.01% 3089
2024
Q3 		$10.5K Hold
1,508
– – ﹤0.01% 3262
2024
Q2 		$11.4K Buy
+1,508
New +$15.2K ﹤0.01% 3269
2022
Q2 		– Sell
-730
Closed -$6K – 3612
2022
Q1 		$6K Hold
730
– – ﹤0.01% 3490
2021
Q4 		$7K Hold
730
– – ﹤0.01% 3519
2021
Q3 		$12K Hold
730
– – ﹤0.01% 3417
2021
Q2 		$17K Buy
+730
New +$16.9K ﹤0.01% 3349

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Legal & General Group's NPCE Position: Q2 2026 in Review

Legal & General Group increased its Neuropace (NPCE) stake by 18% in Q2 2026, buying an estimated $6.37K and bringing the position to 2,586 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2832.

Legal & General Group first reported a position in NPCE in Q2 2021 and has held it in 13 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Legal & General Group held 2,586 shares of Neuropace worth $41.1K as of Q2 2026.
  • Legal & General Group bought 396 Neuropace shares in Q2 2026, an estimated $6.37K.
  • Neuropace made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2832 holding.
  • Legal & General Group first reported a position in Neuropace in Q2 2021 and has held it in 13 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.